Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT00411645
A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants.
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Clinical Professor, Medicine - Infectious Diseases
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and of Pediatrics (Stem Cell Transplantation)
Inclusion Criteria:
- Allogeneic stem cell transplant recipient
- Recipient or donor CMV seropositive
- Have transplant engraftment
- Able to swallow tablets
Exclusion Criteria:
- CMV organ disease
- HIV infection
- Use of other anti-CMV therapy post-transplant
drug: maribavir
other: placebo
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Janice Brown
6507230822